to evaluate the efficacy of propafenone for suppression of recurrent paroxysmal symptomatic atrial fibrillation ( af ) , patients with frequent episodes of af entered an open-label , dose-ranging study to determine the maximal tolerated dose of propafenone and were subsequently randomized to alternate between propafenone and placebo every month for 4 months .
C0004238
af
C0033429
propafenone